All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.

2023-11-17T11:46:07.000Z

Guest article | Management of psoriasis and psoriatic arthritis in patients with comorbidities: A focus on liver disease

Nov 17, 2023
Share:
Learning objective: After reading this article, learners will be able to discuss the evidence for, pathophysiology, and treatment for liver disease in psoriasis and psoriatic arthritis.

Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a guest article from Lija James, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Psoriatic disease is a recognized multi-system disease, and the symptoms vary from one person to another depending on the severity and clinical manifestations of the disease.1 It is well known that psoriatic arthritis (PsA) is closely related to psoriasis (PsO) and can affect the spine, peripheral joints, and entheses. In European patients with PsO, PsA is present in approximately 23% of patients and in 25% of patients with moderate-to-severe PsO.2

Comorbidities

The disease is commonly associated with several comorbidities, including cardiovascular disease (CVD), obesity, metabolic syndrome, liver disease, mood disorders, chronic infections, cancers, osteoporosis, and chronic pain syndromes such as fibromyalgia.3 In a systematic review and meta-analysis of 12 studies, the risk of all-cause mortality was evaluated in patients with PsO. The study found that PsO patients were at a greater risk of all-cause mortality, which increased with the severity of the disease. Further, a significantly higher cancer mortality risk was associated with severe skin disease. The mortality risk associated with liver disease, kidney disease, and infection was significantly higher, regardless of severity. In light of this study, clinicians should take into account comorbidity screening and provide necessary patient counseling as part of their management plan.4

Liver disease

Non-alcoholic fatty liver disease (NAFLD) is a broad term for the accumulation of fat in the liver. A healthy liver should contain very little fat or none. As NAFLD progresses, it can manifest in several stages, from simple steatosis (fat accumulation), steatohepatitis (liver injury with inflammation), to cirrhosis (irreversible fibrosis from increased collagen deposition), and hepatocellular carcinoma.5

Recently, an international panel using a consensus-driven process proposed a concept for a new multi-systemic condition called ‘Metabolic Dysfunction-Associated Fatty Liver Disease’ (MAFLD), which includes metabolic disorders and is independent of alcohol consumption (Figure 1).6 The diagnostic criteria do not require the absence of other liver diseases (unlike NAFLD).5 This reflects the complex metabolic dysregulation pathways involved in this disorder, and it may be helpful in identifying patients at high risk for this condition.7

Figure 1. Metabolic Dysfunction-Associated Fatty Liver Disease*

HDL, high-density lipoprotein; MAFLD, metabolic dysfunction-associated fatty liver disease.
*Adapted from Gofton et al.5

Evidence of liver disease in PsO and PsA

The prevalence of MAFLD is increasing, making it important to study liver disease in patients with psoriatic disease. In the UK, one in three people suffers from the early stages of NAFLD.8 Several studies have linked PsO to NAFLD in adult patients from the U.S.,9 Holland,10 and South-Asian regions.11 A meta-analysis of 249,933 patients with PsO published in 2022 found that the PsO group had a nearly two-fold increased risk of developing NAFLD compared to the control group. Also, patients with NAFLD had more severe skin disease, measured by the psoriasis area and severity index.12

The relationship between liver disease and PsA has, however, been examined in limited studies. The results of a systematic review of three case-control studies concluded that patients with PsA are at increased risk of developing NAFLD (odds ratio [OR]: 2.25, 95% CI 1.37–3.71).13 The most significant study that explored this further was a cohort study (PsO, n = 197,130; PsA, n = 12,308; and rheumatoid arthritis [RA], n = 54,251) in which the outcomes were assessed in terms of any liver disease, NAFLD, and cirrhosis. According to PsO results, the patients had a greater chance of developing advanced liver fibrosis than matched controls. Secondly, the overall prevalence of liver disease was related to the severity of PsO based on the body surface area. There was an increased risk of NAFLD among PsO and PsA patients, even among those who had not been exposed to systematic therapy.14

Pathophysiology

The causal relationship between psoriatic disease and frequently observed comorbidities is not fully understood. Many of the comorbid conditions share similar 'risk factors', including insulin resistance and other metabolic mechanisms such as inflammation and fibrosis.15 A chronic low-grade inflammatory state appears to be the most significant link between MAFLD and psoriasis.16 A U.S. study further concluded that patients with hepatic steatosis were more likely to develop fibrosis if they were insulin-resistant. An imaging study combined with serological markers showed that insulin resistance can lead to fatty acid accumulation, resulting in 'lipotoxicity'. In turn, oxidative damage leads to inflammation and fibrosis, emphasizing the importance of the relationship between metabolic aspects of the disease and liver fibrosis.17

Several molecular studies have been conducted to identify common cytokine pathways involved in inflammation. Tumor necrosis factor-alpha (TNF-a), interleukin 23 (IL-23), and IL-17 are pro-inflammatory cytokines that play a significant role in both the onset and progression of PsA18. In particular, IL-17 may be the pathogenic link between psoriasis and MAFLD. As well as inducing hepatic inflammation via T cell-mediated responses, IL-17 has also been shown to cause insulin resistance in mouse models.19,20 Additionally, clinical studies have shown that inflammation in PsO extends deeper than the skin, with high levels of these cytokines and activated immune cells found in the serum and other organs.21

Treatments

There are a few key considerations when deciding treatment for patients with liver disease. Commonly used conventional disease-modifying anti-rheumatic drugs, such as methotrexate, have shown to cause liver disease.

Gelfand et al. published the first population-based cohort study comparing patients with PsO, PsA, and RA receiving methotrexate after adjusting for comorbidities and methotrexate dose. Patients with PsO receiving methotrexate were significantly more likely to develop mild liver disease (hazard ratio [HR], 2.22), moderate to severe liver disease (HR, 1.56), cirrhosis (HR, 3.38), and hospitalization due to cirrhosis (HR, 2.25) compared with patients with RA receiving methotrexate. Additionally, the PsA group had significantly elevated risk of mild liver disease (HR, 1.27) and cirrhosis (HR, 1.63) compared with the RA group. A key message from this study is to emphasize that patients with PsO receiving methotrexate were more likely to develop liver disease than patients with RA receiving methotrexate. Therefore, strict liver monitoring is recommended for these patients.22

There are multiple mechanisms responsible for hepatotoxicity in biological and synthetic disease-modifying anti-rheumatic drugs, which makes drug-induced liver injury (DILI) a challenge. For example, hepatocellular and cholestatic patterns of injury, reactivation of hepatitis B, and autoimmune hepatitis are common for all anti-TNF inhibitors used in psoriatic disease.23 While some treatments adversely affect the liver, others are helpful and are associated with improved liver outcomes. This is thought to be linked to liver inflammation secondary to disease activity.

A recent study showed 82% of patients with PsO (n = 65) had MAFLD. The median psoriasis area and severity index were 11.5 and 6.3 in patients with MAFLD and no MAFLD, respectively. This confirms the risk of liver disease associated with inflammation in PsO and that it is not confined to the skin lesions. Moreover, when treated with an IL-17 inhibitor, the NAFLD fibrosis score improved.24 Therefore, treatment with the right medication not only results in achieving minimal disease activity but also reduces the burden of comorbidities, modifies metabolic risk factors, and improves overall health-related quality of life.

Conclusion

Patients with PsO and PsA have a high prevalence of liver disease, specifically MAFLD. The comorbidities associated with this disease affect more than just physical health. A number of targeted therapeutics are currently available that are effective in treating the disease and associated MAFLD. A multidisciplinary approach and a tailored approach are needed to make the best therapeutic decision for psoriatic disease.

  1. Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond) 2017; 17(1): 65-70.
  2. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1): 251-65 e19.
  3. Campanholo CB, Maharaj AB, Corp N, et al. Management of psoriatic arthritis in patients with comorbidities: An updated literature review informing the 2021 GRAPPA treatment recommendations. J Rheumatol. 2023;50(3):426-432.
  4. Dhana A, Yen H, Yen H, et al. All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(5):1332-43.
  5. Gofton C, Upendran Y, Zheng MH, et al. MAFLD: How is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl):S17-S31.
  6. Pipitone RM, Ciccioli C, Infantino G, et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023;14:20420188221145549.
  7. Kudaravalli P, John S. Nonalcoholic fatty liver. StatPearls. Treasure Island (FL); 2023.
  8. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290): 2212-2224.
  9. Ruan Z, Lu T, Chen Y, et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA Dermatology. 2022;158(7):745.
  10. van der Voort EA, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70(3):517-524.
  11. Niriella MA, Ediriweera DS, Withanage MY, et al. Prevalence and associated factors for non-alcoholic fatty liver disease among adults in the South Asian Region: a meta-analysis. Lancet Reg Health Southeast Asia. 2023;15:100220.
  12. Bellinato F, Gisondi P, Mantovani A, et al. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2022;45(7):1277-1288.
  13. Candia R, Ruiz A, Torres-Robles R, et al . Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29(4):656-662.
  14. Ogdie A, Grewal SK, Noe MH, et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid Arthritis: A population-based study. J Invest Dermatol. 2018;138(4):760-767.
  15. Colling R, Verrill C, Fryer E, et al. Discrepancy rates in liver biopsy reporting. J Clin Pathol. 2014;67(9):825-827.
  16. Gisondi P, Bellinato F, Girolomoni G, et al. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-Metabolic Comorbidities. Front Pharmacol. 2020;11:117.
  17. Bae JC, Beste LA, Utzschneider KM. The impact of insulin resistance on hepatic fibrosis among united states adults with non-alcoholic fatty liver disease: NHANES 2017 to 2018.Endocrinol Metab (Seoul) 2022;37(3):455-465.
  18. Lee BW, Moon SJ. Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment. Int J Mol Sci. 2023;24(14).
  19. Gomes AL, Teijeiro A, Buren S, et al Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2016;30(1):161-175.
  20. Tang Y, Bian Z, Zhao L, et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol 2011; 166(2): 281-90.
  21. Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines 2021; 9(11).
  22. Gelfand JM, Wan J, Zhang H, et al. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study. J Am Acad Dermatol 2021; 84(6): 1636-43.
  23. Shah P, Sundaram V, Bjornsson E. Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review. Hepatol Commun 2020; 4(2): 172-84.
  24. Takamura S, Teraki Y, Katayama E, et al. Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs. Clin Mol Hepatol 2022; 28(2): 269-72.

Your opinion matters

HCPs, what is your preferred format for educational content on the PsOPsA Hub?
9 votes - 65 days left ...

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox